eFFECTOR Therapeutics, Inc.

Locust Walk Acquisition Corp (Nasdaq: LWAC), a blank-check company sponsored by Locust Walk Partners and focused on the life sciences sector, filed an 8-K on May 27, 2021 disclosing its definitive business combination agreement with eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company developing targeted therapies that modulate the eIF4F translation pathway in oncology. LWAC completed its IPO in 2020 and pursued targets in the biotechnology and pharmaceutical space. The proposed merger, which was subsequently completed later in 2021, resulted in the combined company trading on Nasdaq under the ticker EFTR. For full filing history, sponsor details, and deal analytics on LWAC and thousands of other SPACs, sign up for SpacDesk at spacdesk.com.